Opalite's bet: AI medical interpreters beat humans, live in 10+ states

Opalite Health sells an AI speech-to-speech medical interpreter that lets providers talk with non-English-speaking patients in 150+ languages, works inside EHR workflows, and auto-drafts visit notes.

That real-time AI can beat certified human interpreters on accuracy at half the price, so hospitals will replace a slow $1–2M-a-year service with software.

Seed stage with Coyote Ventures among investors and Y Combinator W26 backing; amounts not disclosed.

Cathleen Kuo, a physician and the child of non-English-speaking immigrants who translated for her parents as a kid, co-founded Opalite in 2025 with Alex Mehregan, a former Apple engineer who worked on Siri and Apple Intelligence. They joined YC's W26 batch, launched publicly in early 2026, and went live with hospitals, community health centers, home health organizations and telehealth providers.

The pitch targets a real budget line: US hospitals spend up to $1–2M a year on interpretation and federal law (Section 1557 of the ACA) requires language access, while getting a human interpreter can take up to 30 minutes. Opalite charges about $2.95 per interpreted minute against a roughly $5.90 LanguageLine GSA benchmark, and its clinical evaluations reported 1 Spanish error versus 65–93 for certified humans. By July 2026 the company was used daily in 10+ states, with a large healthcare enterprise rollout coming within two months, and customer CIFC Health reported a 50% cut in interpretation costs.

Still scaling: live daily across 10+ US states as of July 2026 and rolling out into a large healthcare enterprise.

Federal law requires language access, so interpretation is a budget line hospitals can't cut — only replace.

Publishing evaluation numbers (1 vs 65–93 errors) reframes the AI claim from hype into an auditable benchmark.

Pricing at half the LanguageLine benchmark makes the swap a finance-office decision, not just a clinical one.

Auto-generated visit notes turn a compliance cost into time saved for providers, making the product harder to rip out.

Pricing a replacement against the incumbent's benchmark and publishing error counts versus humans turns a scary AI claim into a procurement decision a CFO can sign.

As of September 2026, Opalite is an active YC W26 company (team of 3) used daily by patients and providers across 10+ US states, including hospitals, community health centers, home health and telehealth providers; a large healthcare enterprise rollout was slated within two months of its July 2026 launch post. It still faces slow hospital sales: long EHR integrations (Epic, Cerner via FHIR), regulatory questions about AI in clinical settings, and proving accuracy on real visits rather than controlled evaluations.